Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli ...
They both have the same active ingredient in them. Mounjaro and Zepbound, the two Lilly drugs also have the same active ingredient. That one is tirzepatide. But those two drugs differ. Both of ...
Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results